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Abstract
Idiopathic immune thrombocytopenia (ITP) is an autoimmune disorder characterized 
by relapsing/ remitting thrombocytopenia. Bleeding complications are infrequent with 
platelet counts above 30×109/L, and this level is commonly used as a threshold for 
treatment. The question of another/ co- existent diagnosis or an alternate mechanism 
of platelet destruction arises when bleeding is experienced with platelet counts above 
this threshold. We report a case of anti- GPVI mediated ITP that was diagnosed follow-
ing investigations performed to address this key clinical question. A patient with ITP 
experienced exaggerated bruising symptoms despite a platelet count of 91×109/L. 
Platelet functional testing showed an isolated platelet defect of collagen- induced ag-
gregation. Next generation sequencing excluded a pathogenic variant of GP6, and anti- 
GPVI antibodies that curtailed GPVI function were confirmed by extended platelet 
phenotyping. We propose that anti- GPVI mediated ITP may be under- recognized, and 
that inclusion of GPVI in antibody detection assays may improve their diagnostic util-
ity and in turn, facilitate a better understanding of ITP pathophysiology and aid indi-
vidualized treatment approaches.
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1  | CASE REPORT
A 41- year- old female presented to our haematology clinic for the in-
vestigation of a platelet function defect characterized by an isolated 
reduction of collagen induced aggregation that had been detected by 
light transmission aggregometry (LTA) in the setting of a long- standing 
history of primary immune thrombocytopenia (ITP). The cause of 
the platelet function defect (PFD) was postulated to be secondary 
Essentials
• Platelet	function	defects	may	cause	atypical	bleeding	symptoms	in	immune	thrombocytopenia	(ITP).
• An	isolated	platelet	defect	of	collagen-induced	aggregation	was	explored	in	a	patient	with	ITP.
• ITP	mediated	by	antibodies	to	glycoprotein	(GP)	VI	curtail	receptor	function.
• Inclusion	of	GPVI	in	diagnostic	antibody	detection	assays	may	improve	their	diagnostic	utility.
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to an acquired autoantibody in the setting of ITP or to an inherited 
glycoprotein (GP) VI mutation. The undefined nature and clinical sig-
nificance of the platelet defect had delayed surgery in the past and 
hence diagnosis was important to inform future treatment, and pre-
dict bleeding risk.
Immune thrombocytopenia had been diagnosed 19 years prior 
following mucocutaneous bleeding associated with a platelet count of 
10×109/L. Subsequent full blood count examinations, bone marrow 
biopsy and response to immunosuppression were consistent with 
this diagnosis. Six years before her referral she received pulsed high 
dose corticosteroid, as well as intravenous immunoglobulin followed 
by dapsone for a relapse of severe thrombocytopenia (platelet count 
2×109/L). This approach had achieved a complete response and dap-
sone was later ceased electively. No other treatment for ITP had 
been required following that period. Other medications included 
low dose amitryptiline (12.5 mg nocte) for chronic pain relating to 
F IGURE  1 Patient platelet morphology and function. (A) Representative image of a blood film (100× magnification) demonstrating normal 
platelet (black arrows), red cell (black arrow head), monocyte (red arrow), and lymphocyte (red arrow head) morphology. (B) Platelet responses 
to agonists, collagen (Coll) (0.5 and 1.0 μg/mL), adenosine diphosphate (ADP) (2.5 and 5 μmol/L), arachidonic acid (AA) (0.5 mg/mL), epinephrine 
(Epi) (5.5 mol/L) and ristocetin (Risto) (0.5 and 1.5 mg/mL) as measured by LTA are shown for the patient (top) and healthy control (bottom). (C) 
Flow cytometry of patient platelets (blue dot plots) and a healthy donor (green dot plot) demonstrating reduced GPVI platelet surface expression 
on patient platelets. (D) Intact GPVI was detectable by western blot of non- treated (NT) washed platelet lysates from a healthy donor (control) 
but not at three different loadings of platelet lysates from the patient (Pt; lanes labelled *Pt were loaded with equivalent volumes of lysate). 
Treatment with 5 mmol/L NEM for 15 minutes (+NEM) to cause shedding of GPVI enabled detection of a ~10 kDa band (GPVI c.tail)
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osteonecrosis of the hip following steroid treatment, and alprazolam 
(0.5 mg) for insomnia.
Platelet function studies were requested prior to elective laparo-
scopic pelvic surgery, due to bruising symptoms that were inconsis-
tent with the degree of thrombocytopenia (platelet count 91×109/L). 
Results of the LTA confirmed a PFD with absent platelet responses to 
collagen (1.25 μg/mL), with only slow and reduced response to this 
agonist at a higher concentration (6 μg/mL). Normal aggregation was 
noted with adenosine diphosphate (2.5 μmol/L) and arachidonic acid 
(1.6 mmol/L).
At the time of our initial consultation, the patient’s full blood count 
demonstrated mild thrombocytopenia with no other abnormalities evi-
dent on the peripheral blood film (Figure 1A). ITP screening blood tests1 
were repeated and excluded an underlying inflammatory condition or 
secondary acquired cause for thrombocytopenia. An isolated plate-
let defect in response to collagen was confirmed by LTA (Figure 1B). 
Platelet flow cytometry demonstrated normal surface expression of 
GPIb- IX, integrin αIIbβ3, GPIV, and α2β1 with reduced expression of 
the collagen receptor GPVI (Figure 1C) and Western blots of patient 
platelet lysates using an anti- GPVI cytoplasmic tail antibody confirmed 
the absence of both intact (60- kDa band) and cleaved GPVI (~10- kDa 
band) respectively (Figure 1D). Next generation sequencing was per-
formed, and excluded a mutation in the coding sequence of GPVI.
To determine the presence of anti- GPVI antibodies and elucidate 
their mechanism of action additional investigations were performed. 
Aggregation of donor platelets by patient serum was demonstrated by 
mixing 1:1 volume/volume with washed donor platelets. Rapid aggre-
gation was noted which was blocked by pre- incubation of donor plate-
lets with either 10 μg/mL IV.3 (function blocking monoclonal antibody 
against FcγRIIa) or by pre- treatment of donor platelets with 1 mmol/L 
NEM (a non- specific treatment of platelets which induces metallopro-
teolytic shedding of GPVI). NEM- treated platelets remained respon-
sive to ristocetin demonstrating GPIb- IX- V and associated signalling 
pathways were functional, and indicating that the aggregating prop-
erty of patient serum required functional FcγRIIa and intact GPVI 
(Figure 2A). These data are consistent with patient serum containing 
an anti- GPVI autoantibody that caused platelet activation requiring an 
intact GPVI/ FcγRIIa complex.
Flow cytometry of donor platelets incubated for 3 hours with 
control or patient serum was performed to evaluate whether patient 
serum could induce loss of platelet surface receptors (GPVI and 
others) from donor platelets. Expression levels of platelet surface 
receptors on donor platelets were monitored by flow cytometry. 
Incubation with patient but not control serum resulted in significant 
generation of microparticles, and so all measured platelet recep-
tors (αIIbβ3, GPIbα, CD9, and GPVI) were reduced, however GPVI 
was clearly highly susceptible to loss by this treatment with 79% 
receptor clearance occurring during the experimental time frame 
(Figure 2B). Taken together, this data confirmed a rare occurrence 
of an anti- GPVI autoantibody that engages both GPVI and FcγRIIa 
leading to platelet activation and aggregation. The observed loss 
of GPVI is probably via immunoreceptor tyrosine- based activation 
motif (ITAM)- mediated metalloproteolytic shedding as described in 
other cases.2,3
2  | DISCUSSION
Primary ITP is an acquired thrombocytopenia that is not associ-
ated with a systemic trigger including viral infection, connective 
tissue disorder, drug therapy, or lymphoproliferative neoplasm).1 
Thrombocytopenia ensues following platelet destruction that is medi-
ated by the production of platelet specific immunoglobulin- G (most 
commonly targeting platelet αIIbβ3 and GPIb- IX) by B- lymphocytes, as 
well as, reduced platelet production secondary to T- lymphocyte medi-
ated platelet, and megakaryocyte cytotoxicity.4
F IGURE  2 Patient serum aggregates donor washed platelets in an FcγRIIa- and GPVI- dependent manner. Washed platelets were prepared 
as described previously18 and light transmission aggregometry was performed. (A) Patient serum was mixed with an equal volume of donor 
platelets or donor platelets pre- treated with 10 μg/mL FcγRIIa- blocking antibody IV.3 or 1 mmol/L NEM to remove GPVI. NEM- treated platelets 
did not aggregate in the presence of patient serum but aggregated upon addition of 1.5 mg/mL ristocetin. (B) Flow cytometry of donor platelets 
using anti- GPVI monoclonal antibody 1G5 to detect GPVI after 3 hours’ incubation at 37°C with equal volume of patient serum (filled histogram) 
or control serum (open histogram)
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GPVI is an integral platelet surface receptor that is expressed in 
a non- covalent complex with the platelet Fc receptor γ chain (FcRγ).5 
Surface expression and function of GPVI is dependent on its asso-
ciation with FcRγ.6 Binding of GPVI by agonists that include colla-
gen, collagen- related peptide, and snake toxins7,8 induce structural 
changes of both GPVI and FcRγ leading to phosphorylation of Src and 
Syk tyrosine kinases.8 These in turn initiate an intracellular signaling 
pathway causing eventual shape change and activation of integrin 
αIIbβ3 with resultant platelet aggregation mediated by αIIbβ3 binding 
of von Willebrand factor or fibrinogen.8
Autoantibodies to GPVI have been reported in ITP9–13 and as in 
our case, activate platelets in a GPVI/ FcRγIIa complex dependent 
manner.13 Subsequent loss of platelet surface GPVI causing reduced 
responsiveness to collagen is likely mediated through autoantibody 
engagement of GPVI and FcRγIIa that results in metalloproteolytic 
shedding of GPVI by ADAM10 on platelets.3,13
The diagnosis of ITP is made following exclusion of secondary 
causes of thrombocytopenia, as there is no single diagnostic assay.1,4 
Routine use of antiplatelet antibody assays, such as the monoclo-
nal antibody immobilization of platelet antigens assay (MAIPA), that 
measures antibodies bound to specific platelet glycoproteins for the 
diagnosis ITP is not recommended, due to lack of reported sensitiv-
ity (50%- 80%) and specificity (80%) of this platform in the setting of 
ITP.1,14 The standard MAIPA platform measures antibodies bound to 
platelet antigens, αIIbβ3 and GPIb- IX, and does not include antibodies 
to α2β1 and GPVI, although the latter have both been described in 
cases of ITP.9–13,15 It is feasible that the sensitivity and specificity of 
this assay may be improved by the addition of these additional an-
tigenic targets into standard MAIPA platforms, thereby validating its 
use for diagnostic purposes. The identification of anti- platelet anti-
bodies at diagnosis has been reported to be associated with a higher 
likelihood of disease chronicity and bleeding symptoms.16 Therefore, 
the utility of these assays prospectively could also potentially impact 
treatment and monitoring strategies.
Major bleeding including intracerebral haemorrhage is rare in 
ITP and occurs predominantly in patients with platelet counts below 
10×109/L.17 A platelet count of less than 30×109/L is generally 
regarded as a threshold for treating ITP.1 Thrombopoietin (TPO) 
regulates thrombopoiesis through activation of TPO receptors on 
the megakaryocyte cell surface, resulting in increased platelet pro-
duction. Two second generation TPO agonists, Eltrombopag and 
Romiplostim, are approved for the treatment of ITP.1 Romiplostim 
treatment may directly upregulate the expression of platelet GPVI 
through receptor- mediated demethylation of the GP6 promoter.18 
Moreover, Gardiner and colleagues19 reported normalized GPVI 
levels and platelets responses to collagen by LTA in a patient with 
anti- GPVI mediated ITP following 6 months of treatment with 
Romiplostim. This case illustrates that anti- GPVI antibodies can 
impair receptor function contributing to increased mucocutane-
ous bleeding symptoms at platelet counts above the threshold of 
30×109/L. Taken together therefore, identification of anti- GPVI an-
tibodies at diagnosis may aid treating clinicians to elect to pursue 
closer surveillance schedules, or even embark on “disease”- specific 
therapies with TPO agonists at platelet counts higher than the ac-
cepted threshold.
Finally, this case demonstrates the utility of genetic based testing 
in uncharacterized platelet disorders. In our report, the absence of a 
GP6 mutation suggested that an acquired rather than inherited PFD 
was responsible for the loss of GPVI expression. Moreover, it provided 
reassurance to the patient who had concerns regarding transmission 
of a possible clinically significant variant to offspring.
In summary, we describe a rare case of anti- GPVI mediated ITP 
and showed that these antibodies not only cause initial platelet ac-
tivation, but result in loss of platelet surface GPVI causing clinically 
appreciable platelet dysfunction that is characterized by mild bleeding 
symptoms at platelet counts not usually associated with bleeding in 
ITP. In the case described here, elective surgery was delayed due to 
concerns of the etiology and significance of the patient’s platelet de-
fect. Ultimately an alternate non- surgical treatment strategy was pur-
sued which facilitated investigation and identification of the patient’s 
platelet dysfunction. Future peri- operative care will be guided by rec-
ommendations for the management of mild bleeding disorders.20
We propose that anti- GPVI mediated ITP may be underappreci-
ated, as LTA is generally not performed for bleeding symptoms asso-
ciated with ITP, and probably more significantly, GPVI is not currently 
included in standard MAIPA assays. Inclusion of GPVI as a protein tar-
get, together with other known antigenic markers (α2β1), may improve 
diagnostic utility of this assay, provide prognostic information and may 
facilitate individualized treatment approaches.
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